NKF Spring Clinical Meetings 2025
Advertisement
Joel Topf spoke with Mini Michael about the ILLUMINATE-B study of lumasiran for PH1 in infants and young children.
Joel Topf spoke with dietitian Melanie Betz about potassium, oxalate, and other renal nutrition concerns.
Joel Topf spoke with Areef Ishani about kidney stone outcomes from the Diuretic Comparison Project, a study of US veterans.
Joel Topf spoke to Seldin Award winner Roger Rodby at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke with Kathleen Liu about acute kidney injury and other topics ahead of her Massry lecture at SCM25.
We spoke to David M. Hume Award winner Bradley Warady, MD, at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke to onconephrologist Meghan Sise about her carboplatin dosing research at SCM25.
Joel Topf caught up with James Tumlin at NKF SCM25 to talk about Dr. Tumlin's late-breaking abstract on sparsentan in FSGS.
Joel Topf spoke with Lazarus Award winner Jeffrey Perl at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke with Connie Rhee at SCM25 about her study on cognitive function with dialysis vs conservative CKD management.
Joel Topf spoke with Bradley Marder of Amgen about gout studies at the NKF Spring Clinical Meetings 2025.
A survey sought insight on nephrologists' practices and perceptions about reproductive care for women with kidney disease.
Joel Topf spoke to Excellence in Transplantation Award winner Jayme Locke at the National Kidney Foundation SCM25.
A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease.
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
One-year results of the AFFINITY trial of atrasentan to treat proteinuria among patients with IgAN were presented at SCM25.
The National Kidney Foundation (NKF) announced the Spring Clinical Meetings 2025 (SCM25) Outstanding Poster honorees.
Researchers presented results of an interim analysis of a study of finerenone among patients with CKD and type 2 diabetes.
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Researchers assessed the burden of cardiovascular-kidney-metabolic (CKM) syndrome using NHANES 2001-2020 data.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.